Surrozen (SRZN) Free Cash Flow (2020 - 2026)
Surrozen (SRZN) recorded quarterly Free Cash Flow of -$12.6 million in Q1 2026, down 108.34% quarter-over-quarter from -$6.1 million in Q4 2025, and down 35.25% on a YoY basis from -$19.5 million in Q1 2025.
Surrozen (SRZN) Free Cash Flow (2020 - 2026) Analysis & Trends
Surrozen's Free Cash Flow history runs 7 years deep, the most recent figure standing at -$12.6 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 35.25% year-over-year to -$12.6 million; the TTM figure through Mar 2026 stood at -$33.8 million (down 85.48% YoY), while the FY2025 annual figure was -$30.5 million, down 73.34% from the prior year.
- Free Cash Flow was -$12.6 million for Q1 2026 at Surrozen, down from -$6.1 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $3.5 million in Q4 2024 to a low of -$18.4 million in Q1 2022.
- Historically, Free Cash Flow has averaged -$8.6 million across 5 years, with a median of -$8.8 million in 2023.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow slumped 2279.1% in 2023, then jumped 148.04% in 2024.
- A 5-year view of Free Cash Flow shows it stood at $335000.0 in 2022, then plunged by 2279.1% to -$7.3 million in 2023, then surged by 148.04% to $3.5 million in 2024, then sank by 272.65% to -$6.1 million in 2025, then slumped by 108.34% to -$12.6 million in 2026.
- The last three Free Cash Flow figures came in at -$12.6 million (Q1 2026), -$6.1 million (Q4 2025), and -$9.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 63,220.27 |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | -12.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.62 Mn |
| Mar 31, 2026 | -12.62 Mn |
| Dec 31, 2025 | -6.06 Mn |
| Dec 31, 2025 | -6.06 Mn |
| Sep 30, 2025 | -9.02 Mn |
| Sep 30, 2025 | -9.02 Mn |
| Jun 30, 2025 | -6.12 Mn |
| Jun 30, 2025 | -6.12 Mn |
| Mar 31, 2025 | -9.33 Mn |
| Mar 31, 2025 | -9.33 Mn |
| Dec 31, 2024 | 3.51 Mn |
| Dec 31, 2024 | 3.51 Mn |
| Sep 30, 2024 | -6.75 Mn |
| Sep 30, 2024 | -6.75 Mn |
| Jun 30, 2024 | -5.66 Mn |
| Jun 30, 2024 | -5.66 Mn |
| Mar 31, 2024 | -8.71 Mn |
| Mar 31, 2024 | -8.71 Mn |
| Dec 31, 2023 | -7.30 Mn |
| Dec 31, 2023 | -7.30 Mn |